Yatırımcı.AI

ECILC vs MEDTR Comparison

Price, market cap, valuation, profitability and leverage metrics of ECILC and MEDTR side by side.

ECILCMEDTR
StockFund

If You Had Invested TRY 10,000

Metric Comparison

ECILC vs MEDTR Comparison
MetricECILCMEDTRSector median
Last price (TL)64.0518.1718.72
Daily change−6.50%−6.34%−5.97%
Market capTRY 43.9BTRY 2.2BTRY 4.3B
P/E—66.4317.25
P/B0.680.691.08
Dividend yield2.04%0.44%0.90%
Return on equity−3.08%1.14%1.78%
Free float22.02%20.21%37.21%
Ratios are calculated from the latest published financial statements.

Popular Comparisons

Related Pages

About the ECILC vs MEDTR Comparison

Price, market cap, valuation multiples, profitability and leverage of ECILC (Eczacıbaşı İlaç) and MEDTR (Meditera Tibbi Malzeme) side by side as of Sep 28, 2026, 15:49. Of the 14 metrics compared, ECILC leads in 5 and MEDTR leads in 9.

Highlights: Daily change: MEDTR leads (−6.34% vs −6.50%). Market cap: ECILC leads (TRY 43.9B vs TRY 2.2B). P/B: ECILC leads (0.68 vs 0.69). EV/EBITDA: MEDTR leads (7.60 vs 165.19). EV/Sales: MEDTR leads (1.36 vs 9.35). Dividend yield: ECILC leads (2.04% vs 0.44%). Gross margin: ECILC leads (37.83% vs 33.71%). EBITDA margin (annual): ECILC leads (11.49% vs 3.58%).

Frequently Asked Questions

By P/E, Tie is cheaper (— vs 66.43); by P/B, ECILC trades at the lower multiple (0.68 vs 0.69).

Annual net margin is −20.86% for ECILC and 1.35% for MEDTR; return on equity is −3.08% for ECILC and 1.14% for MEDTR.

The leverage ratio is 18.92 for ECILC and 15.79 for MEDTR; net debt/EBITDA is 1.37 for ECILC and — for MEDTR. Lower values mean less leverage.

Prices and market caps come from 15-minute delayed Borsa Istanbul data; ratios are calculated from the latest financial statements filed with KAP. Some ratios are not defined for banks and insurers.